Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Tumour heterogeneity and its influence on cancer and immune therapy responses

Genomic determinants and tumour heterogeneity of checkpoint inhibitor response

Date

17 Oct 2020

Session

Tumour heterogeneity and its influence on cancer and immune therapy responses

Topics

Immunotherapy;  Basic Science

Tumour Site

Presenters

Nicholas McGranahan

Authors

N. McGranahan

Author affiliations

  • UCL Cancer Institute/Paul O'Gorman Building, WC1E 6JD - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.